The start-up is built around four business units – technology, manufacturing, R&D and therapeutics – based on internal and external expertise. Kriya will take its first gene therapies into the clinic in 2023. 

Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.

Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.

The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.